J&J seeks to market Doxil for breast cancer in the U.S.

09/8/2008 | Bloomberg

Johnson & Johnson applied for FDA approval for the use of its cancer drug Doxil combined with Sanofi-Aventis' Taxotere in women who have advanced breast cancer. The combination therapy is intended for patients who already received anthracycline, a standard chemotherapy medicine, J&J unit Ortho Biotech Products said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID